The Fas counterattack: cancer as a site of immune privilege
- 1 January 1999
- journal article
- review article
- Published by Elsevier in Immunology Today
- Vol. 20 (1), 46-52
- https://doi.org/10.1016/s0167-5699(98)01382-6
Abstract
No abstract availableThis publication has 105 references indexed in Scilit:
- The host—tumor immune conflict: from immunosuppression to resistance and destructionImmunology Today, 1997
- A CASP-8 Mutation Recognized by Cytolytic T Lymphocytes on a Human Head and Neck CarcinomaThe Journal of Experimental Medicine, 1997
- Resistance of cultured peripheral T cells towards activation‐induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death‐inducing signaling complexEuropean Journal of Immunology, 1997
- Apoptosis by Death FactorCell, 1997
- Interferon-γ InducesIceGene Expression and Enhances Cellular Susceptibility to Apoptosis in the U937 Leukemia Cell LineBiochemical and Biophysical Research Communications, 1996
- A role for CD95 ligand in preventing graft rejectionNature, 1995
- Fas(CD95)/FasL interactions required for programmed cell death after T-cell activationNature, 1995
- Expression of the co‐stimulatory molecule B7 on melanoma cellsInternational Journal of Cancer, 1994
- Biosynthesis and shedding of murine lymphoma gangliosidesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1993
- Costimulation of T cells for tumor immunityImmunology Today, 1993